Mediklin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mediklin

What is Mediklin?

Mediklin is a topical dermatological treatment formulated to manage inflammatory acne vulgaris. It belongs to a class of medications designed to address the underlying factors that contribute to the development and progression of acne lesions.

Composition and Action

The primary therapeutic component of Mediklin is clindamycin, a lincosamide antibiotic. When applied to the skin, it works by inhibiting the protein synthesis of bacteria associated with acne, most notably Cutibacterium acnes. By reducing the population of these bacteria within the sebaceous follicles, the medication helps to decrease the secondary inflammation that leads to visible skin breakouts.

Clinical Applications

Mediklin is typically utilized for the following conditions:

  • Inflammatory Acne: Treatment of papules and pustules (red bumps and whiteheads).
  • Bacterial Control: Reduction of bacterial colonization on the skin surface and within pores.
  • Inflammation Reduction: Limiting the redness and swelling associated with acne flare-ups.

Formulation Characteristics

This medication is commonly available in gel or solution forms. These vehicles are designed to facilitate the penetration of the active ingredient into the affected pores while maintaining a localized effect. The formulation is intended for external use only and is structured to provide a consistent delivery of the antibiotic to the site of inflammation.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Mediklin?

Possible Side Effects and Safety Information

The safety profile for Mediklin (topical Clindamycin Phosphate) is officially documented by regulatory authorities, classifying adverse events primarily by their frequency and the system they affect.

Frequency-Classified Adverse Reactions

The most frequently reported effects are localized to the skin at the site of application. Regulatory documents classify these reactions as follows:

Classification Examples of Documented Effects
Very Common Dry skin
Common Application site irritation, abdominal pain, oily skin, urticaria (hives)
Uncommon Contact dermatitis

Systemic Safety Considerations

Due to the potential for systemic absorption, the official labeling includes critical warnings for serious gastrointestinal disorders, which are classified under Gastrointestinal Disorders. These potentially severe adverse reactions include Pseudomembranous colitis and Clostridioides difficile-associated diarrhea (CDAD). These severe effects have been reported to occur not only during treatment but also weeks after the cessation of therapy, a time-related pattern noted in the safety profile.

Safety Restrictions and Precautions

Mediklin is contraindicated in individuals with a history of sensitivity to clindamycin or lincomycin. It is also restricted for use in those with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Caution is advised regarding use during pregnancy and lactation, where treatment is typically recommended only if clearly necessary.

Overdose and Emergency Response

Overdose and When to Seek Help

Mediklin is a topical gel containing clindamycin and tretinoin, and excessive application is unlikely to result in acute, life-threatening systemic overdose due to minimal absorption through the skin. However, using significantly more than the prescribed amount or more frequently than directed will not hasten results but may increase the risk of pronounced local side effects.

Symptoms of Excessive Topical Use

Overuse, particularly with the tretinoin component, may lead to exaggerated signs of local irritation, including:

  • Severe redness and peeling of the skin
  • Significant dryness or flakiness
  • Intense burning or stinging sensation

Accidental Ingestion

While this medication is for external use only, accidental oral ingestion could potentially lead to systemic side effects related to clindamycin, such as gastrointestinal upset.

When to Seek Immediate Medical Attention

Stop using the gel and seek emergency medical attention if you experience signs of a severe allergic reaction or other serious complications, which can occur with clindamycin-containing products:

  • Difficulty breathing or swallowing
  • Swelling of the face, lips, tongue, or throat
  • Widespread blistering, peeling, or crusting of the skin
  • Severe, persistent, or bloody diarrhea or stomach cramps (even several weeks after stopping use)

In the event of accidental ingestion or suspicion of overdose, contact a poison control center immediately.

Therapeutic Uses of Mediklin

What Mediklin Treats: Main Uses and Benefits

Mediklin is a topical combination medication primarily used for managing acne vulgaris, a condition characterized by periods of heightened symptoms. Its active components are applied across therapeutic domains where additional symptomatic support is needed. The product is indicated for use when symptoms of the condition are present, including comedones, papules, and pustules. This application is often used during phases when symptoms become more noticeable.


The formula is relevant for easing symptom clusters that may become intense or disruptive, especially those related to inflammatory or irritative states and physical discomfort. This supportive relief generally helps patients cope more steadily with symptom fluctuations. The treatment approach assists with maintaining functional stability when symptoms interfere with routine activities. The combination is relevant in contexts involving heightened systemic burden, providing support that helps ease the overall symptom burden.

Quick Facts: The treatment assists with maintaining functional stability and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Mediklin (Clindamycin Phosphate topical) is officially designated for use in adults and adolescents aged 12 years and older. Its eligibility is strictly defined by regulatory documentation, which outlines specific populations who are restricted, contraindicated, or in whom safety has not been fully established.

Contraindications and Prohibitions

Use is absolutely contraindicated in individuals with a known hypersensitivity or allergy to clindamycin or lincomycin. The medicine must also not be used by patients with a history of specific gastrointestinal diseases, including regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Conditional and Age-Based Restrictions

For pediatric patients under the age of 12 years, the safety and effectiveness have not been established according to regulatory labeling, and use is generally not recommended. In terms of reproductive status, use during the first trimester of pregnancy is restricted to only when clearly needed. For nursing mothers, official labeling mandates a decision to either discontinue the drug or discontinue breastfeeding. Furthermore, caution is advised for atopic individuals and for patients concurrently using neuromuscular blocking agents, as these situations represent conditional restrictions in the official eligibility profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Mediklin (Clindamycin topical) is defined by specific administration constraints and pharmacological interactions documented in official regulatory sources. These documented interactions fall into categories of prohibited combinations, potentiation risks, and mandatory timing separation.


  • Contraindicated Combination: Co-administration with the antibiotic Erythromycin is strictly contraindicated by regulatory labeling due to evidence of in vitro pharmacological antagonism. The use of these two substances together is formally discouraged.
  • Pharmacodynamic Potentiation: Clindamycin is officially recognized as having neuromuscular blocking properties. When Mediklin is used alongside other Neuromuscular Blocking Agents (NMBAs), this property may cause an enhanced action of the blocking agent, a risk noted for caution in prescribing information.
  • Administration Timing Restriction: Regulatory documents place a restriction on co-administering Mediklin with other topical acne treatments, including preparations that contain tretinoin or benzoyl peroxide. This restriction is due to the risk of cumulative local irritancy and requires a separation of administration time; the products must be applied at different times of the day.
  • Systemic Interaction Summary: Based on the low systemic exposure associated with the topical formulation, official regulatory labeling does not include mandated warnings for clinically significant pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters. Furthermore, no specific restrictions are documented regarding interactions with food, alcohol, or herbal products.

Mechanism of Action

How Mediklin Works

The pharmacological action of Clindamycin is exerted through a highly specific molecular mechanism that inhibits bacterial replication and suppresses the synthesis of bacterial toxins.


Targeted Inhibition of Bacterial Protein Synthesis

This mechanism is initiated by Clindamycin acting as a specific inhibitor of the fundamental process of bacterial protein creation. The molecule achieves this by specifically binding to the 50S ribosomal subunit within susceptible bacteria, which prevents the essential translocation step in the elongation of peptide chains. This molecular interference immediately stalls bacterial growth and prevents the formation of essential proteins required for bacterial maintenance and division, resulting in a primary bacteriostatic effect.


Modulation of Bacterial Virulence and Local Response

Beyond simply stopping growth, this mechanism has a significant downstream effect on bacterial virulence. By blocking the synthesis of all bacterial proteins, the drug limits the pathogen's ability to produce and secrete toxins and enzymes (virulence factors). This action reduces the release of the inflammatory stimulus in the localized tissue, which, alongside the halt in growth, defines the overall mechanistic control of the bacterial burden.

Dosage and Administration Information

Mediklin, which contains topical clindamycin phosphate, is a medication intended for application directly to the skin, following established administration protocols. The active product is consistently formulated as 1% clindamycin, available in several forms, including a gel, solution, and foam. The approved route is cutaneous only; it is not intended for use via the oral, ophthalmic, or intravaginal routes. The general usage principle is based on local administration to the entire affected area where lesions appear.

The standard schedule requires applying a thin film of the product either once or twice daily, depending on the specific formulation being used. Application must occur only after the treatment area has been washed, rinsed, and gently patted dry. Patients must exercise care to avoid contact with sensitive areas such as the eyes, mouth, lips, and other mucous membranes during administration.

Usage is restricted by age, with the product being indicated for patients 12 years of age and older. The safety and effectiveness of this topical antibiotic have not been established in patients younger than 12. The duration of use is typically assessed by the prescriber, and guidelines often advise re-evaluating the course if no measurable improvement is seen after six to eight weeks of continuous use.


Usage Feature Principle of Administration
Route Topical application only (cutaneous)
Frequency Once or twice daily (Formulation dependent)
Age Rule Indicated for 12 years of age and older
Duration Reassessment after 6 to 8 weeks

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research and Mechanism of Action

Research has explored whether Mediklin (an antibiotic containing clindamycin) interacts with specific cellular receptors to interact with biological processes under study. This is the primary hypothesis guiding current research efforts related to its use in treating dermatologic diseases.

Key Clinical Study Findings

Early studies investigated a reduction in the primary symptom (pain) across study participants. Researchers examined the duration of the change in pain scores. The findings contributed to the design of subsequent research.

A meta-analysis of three Phase 3 trials examined symptom scores when comparing the treatment group to a control group over a 12-week period.

Combination Therapy Studies

Studies have evaluated whether the combination of Drug X and standard treatment Y has an additive effect. Specifically, researchers examined whether the frequency of flare-ups decreased and whether an earlier change in symptoms was observed. The evidence remains limited, and further investigation is required in this area.

Tolerability and Study Data

The tolerability of the drug was characterized in study populations. The review cataloged events reported by study participants. Researchers noted an area for further study regarding participants with kidney function concerns.

Studies examined the tolerability and effect of the highest studied dose (10mg) in participants experiencing severe symptoms. Study data was collected over a period of up to two years.

Quality of Life Research

A recent study reported that participants taking the drug had different quality of life metrics compared to the placebo group. The study specifically assessed parameters related to daily activity and sleep quality. The research parameters included daily activity and sleep quality.

Key Studies & References

  1. Meta-Analysis of Clindamycin Efficacy in Inflammatory Dermatosis: Symptom Scores and 12-Week Outcomes
  2. Study of Dosing Effect and Tolerability of High-Concentration Topical Clindamycin (10mg) in Severe Dermatosis

Frequently Asked Questions (FAQ)

Common questions about Mediklin (FAQ)


Q: If I miss a dose of Mediklin, will it affect the outcome?

If a dose is missed, official prescribing information advises that the application should occur as soon as it is remembered. However, if it is almost time for the next scheduled application, the guidance is to skip the missed dose and resume the regular dosing schedule. The product label notes that extra product should not be used to make up for a missed application.


Q: How quickly should I expect to see any kind of change after starting Mediklin?

While some patients may see initial changes sooner, regulatory documents advise that a patient's response to the treatment should be reviewed by a healthcare provider after a period of six to eight weeks of continuous use. Clinical data indicates that it can often take up to 12 weeks to observe the full effects of the medication.


Q: What kind of research has been done on the long-term effects of Mediklin?

Studies have examined the tolerability and effects of the drug in study participants over periods of up to two years. This research helps characterize the safety profile of the medication during extended use.


Q: Does alcohol affect how Mediklin works?

Due to the low systemic exposure associated with the topical formulation, official regulatory labeling does not include specific restrictions or warnings regarding interactions with alcohol.


Q: How long after stopping Mediklin does it typically stay in the body?

The topical formulation is associated with low systemic exposure, meaning only small amounts enter the bloodstream. This low systemic exposure must be considered in light of reports that serious gastrointestinal reactions have occurred up to several weeks after the cessation of clindamycin therapy.


Q: Is Mediklin considered a new or long-established medicine?

The core active compound, Clindamycin, is a semi-synthetic derivative of the long-established antibiotic Lincomycin. Specific topical gel formulations of the drug have been approved by the FDA since 2000.


Q: What happens if I stop taking Mediklin suddenly?

Stopping the drug may cause the original symptoms to return. Furthermore, serious gastrointestinal disorders, such as a severe type of diarrhea called Pseudomembranous colitis, have been reported to occur even weeks after the cessation of clindamycin therapy.


Q: Is it true that Mediklin only works for a certain percentage of patients?

Clinical trials for the medication report on its efficacy by detailing the percentage of participants who achieved a defined success endpoint, such as 'clear' or 'almost clear' skin, after a specific duration of treatment. These results provide insight into the effectiveness of the drug across the study population.


Q: Can people with mild kidney issues still use Mediklin?

Regulatory labeling advises that the drug should be administered with caution in patients with severely impaired renal function. Monitoring of serum concentrations may be noted as necessary during prolonged or high-dose therapy, but this must be based on individual patient assessment.


Q: Can I use Mediklin if I am also taking vitamins or herbal supplements?

Official labeling does not contain mandated warnings for clinically significant interactions with common vitamins or herbal products. However, it is generally recommended practice to inform a healthcare provider of all medicines, vitamins, minerals, and supplements being taken.


Q: Why does the packaging say that Mediklin must be stored in a specific temperature range?

The drug is formulated to maintain its chemical stability and full strength. Official labeling specifies that protection from freezing or excessive heat is necessary to ensure the stability and potency of the product over its shelf life.


Q: If I am taking Mediklin, can I still donate blood?

Blood donation eligibility depends on the specific reason the drug is being used, not the drug itself. If the drug is being used for common conditions like acne, donation may be acceptable based on standard guidelines, but eligibility is subject to the required screening process at the time of donation.


Q: Does Mediklin interfere with or affect vaccines?

Official labeling indicates an interaction with the live, attenuated oral typhoid vaccine. The product information includes a warning against co-administration of this specific vaccine during and for a specified time before or after treatment with the drug.


Q: Why do some forums discuss a 'Mediklin tolerance' developing?

Official warnings note that, as with all antibiotics, the prolonged use of the cutaneous formulation may lead to the development of bacterial resistance. This is a scientific concept where the target bacteria may become less susceptible to the effects of the antibiotic over time.


Q: How long are people typically advised to stay on Mediklin treatment?

The duration of use is subject to individual patient assessment. However, official guidelines often advise re-evaluating the course if no measurable improvement is seen after six to eight weeks, and the total duration of continuous treatment is typically limited to 12 weeks.


Q: Is there any difference in effect between the brand-name Mediklin and generics?

Generic versions of the active ingredient are available. By regulatory standard, generic drugs must demonstrate bioequivalence to the original brand-name product, meaning they are expected to work in the same way and provide the same clinical benefit.


Q: What if I'm allergic to one of the inactive ingredients in Mediklin?

The drug is strictly contraindicated for use in individuals with a known hypersensitivity or allergy not only to the active ingredients (clindamycin or lincomycin) but also to any of the other ingredients in the specific product formulation.


Q: Does sunlight exposure need to be limited while using Mediklin?

Official warnings describe limiting time in the sun while using the drug. The product information includes precautions such as wearing protective clothing and using sunscreen if sun exposure is unavoidable to minimize potential adverse skin reactions.

How should Mediklin be stored and disposed of?

How to Store and Dispose of Mediklin?

The storage and disposal of clindamycin phosphate topical (Mediklin) must follow conditions specified in official product labeling to maintain stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Must be protected from freezing, excessive heat, and direct sunlight.
Container Keep in the original container, tightly closed, and out of the reach of children.
Flammability Solutions containing alcohol are flammable and must be stored away from sparks or flames.

Disposal Instructions

Mediklin must be discarded when outdated or no longer needed. The pressurized foam canister must not be punctured or burned, even when empty, and should be disposed of according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mediklin found in:

A-Z Index: